Blueprint Presents Positive Ayvakit Data, But Commercial Debate Could Continue

 
• By Alaric DeArment
Blueprint unveiled detailed data for the Phase III PIONEER study of Ayvakit in indolent systemic mastocytosis • Source: Shutterstock

More from Clinical Trials

More from R&D